Zoetis Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 1,589 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• No equity-method, strategic, or unconsolidated investments found. The Q2 2026 10-Q (filed 6 Aug 2026) was searched in full for 'equity method', 'equity securities', 'strategic investment', 'unconsolidated', 'joint venture', 'investment in', 'non-marketable', and 'collaboration'. The FY2025 10-K (filed 12 Feb 2026) was searched with the same terms plus 'other investments'. The only 'equity securities' hits in either filing are (a) issuer repurchases of Zoetis's own stock, and (b) pension-plan asset allocation (equity commingled funds inside the defined-benefit plan trust, not a corporate holding). 'Strategic investment' hits refer only to R&D spending priorities, not equity stakes. 'Joint venture' and 'collaboration' hits (e.g. the 2024 R&D collaboration with Blacksmith Medicines) are licensing/research arrangements; neither filing states that Zoetis purchased shares or holds an equity interest in any collaborator. Zoetis was spun out of Pfizer via IPO in February 2013 and a 2013 split-off exchange; no current parent equity relationship exists, and neither filing mentions a residual Pfizer stake. Holdings is therefore correctly empty, not unresearched.
• Register reconciliation on Vanguard and BlackRock. Zoetis's 2026 proxy (Schedule 13G/A basis, share count as of 20 March 2026) reports The Vanguard Group at 47,778,909 shares (11.36%) and BlackRock, Inc. at 36,492,748 shares (8.68%, from a 13G/A filed 26 Jan 2024 with data as of 31 Dec 2023), the only two holders it identifies as beneficially owning more than 5%. The register instead uses each manager's Q2 2026 Form 13F-HR (30 June 2026 position dates): Vanguard's successor entities sum to 49,888,429 shares and BlackRock reports 39,430,181 shares, both higher than the proxy/13G figures, consistent with position growth between those earlier measurement dates and 30 June 2026 rather than a data error.
• Vanguard Group Inc (CIK 0000102909) filed 13F-NT (notice) for the quarter ended 30 June 2026, consistent with the January 2026 reorganisation of Vanguard's 13F filing structure seen elsewhere in this project (see pnc.json). Per the brief's Vanguard rule this is the 13F-NT case: the register uses the sum of the two successor entities, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC, as a single substituted 'The Vanguard Group' row.
• Capital Group. Checked all three specified Capital Group entities individually for Q2 2026: Capital World Investors (CIK 0001422849) and Capital International Investors (CIK 0001562230) do not hold Zoetis (no name match and no CUSIP 98978V103 match in either filing); Capital Research Global Investors (CIK 0001422848) holds 980,811 shares. The 'Capital Group' register row reflects only the one entity that actually holds the stock.
• Implied price per share was computed for every register row (value_usd / shares) as a thousands-convention check: all thirteen institutional 13F rows cluster tightly at $71.86 per share (Zoetis's 30 June 2026 closing price), so no row required rescaling.
• Zoetis has a single class of common stock ($0.01 par value, one vote per share) and no dual-class or founder-control structure. Insider ownership is immaterial: CEO Kristin C. Peck beneficially owns 492,586 shares (0.117%) and the 22-person director/executive-officer group owns 912,848 shares (0.217%), both under 1% per the proxy's own statement.
• Self-gate: 13 non-member, non-aggregate register rows (all institutional 13F holders; the two insider rows are excluded as members/aggregate of each other) sum to 158,818,732 shares against 413,223,602 shares outstanding, or 38.43%, within the expected 25 to 45 percent range.